Durect
Durect Corp., based in Cupertino, US, innovates pharmaceutical systems for chronic disease treatment, enhancing drug efficacy and safety.
Founded
1998Durect Corp., based in Cupertino, US, innovates pharmaceutical systems for chronic disease treatment, enhancing drug efficacy and safety.
Durect Corp., founded in Cupertino, US, is dedicated to developing and commercializing innovative pharmaceutical systems aimed at treating chronic diseases. The company's core mission is to enhance drug efficacy, reduce side effects, and ensure dosing compliance through advanced therapeutic systems. Durect focuses on harnessing epigenetic modulation to address serious and life-threatening conditions such as acute organ injury and cancer, targeting dysregulated DNA methylation to potentially revolutionize disease treatment and improve patient outcomes.
Notable figures associated with Durect include its experienced leadership team and a network of investors committed to advancing medical innovation. The company has achieved significant milestones in the field of epigenetic therapeutics, positioning itself as a pioneer in this cutting-edge area of medicine. Durect's impact is marked by its potential to transform the treatment landscape for chronic and acute conditions, offering new hope for patients through its groundbreaking approach to drug development.
Companies similar to Durect include Epigentek Group, Corcept Therapeutics, Aquestive Therapeutics and Epirus Biopharmaceuticals.
Durect was founded in 1998.
Durect's headquarters is located in Cupertino, CA, US.
Durect's most recent funding round was for $15M (USD) in July 2023.
As of Jul 20, 2023, Durect has disclosed funding of $77.5M (USD). Undisclosed round amounts are excluded.
Durect has 94 employees as of Feb 6, 2024.
Epirus Biopharmaceuticals
